BMC Cancer 2008, 8:19 http://www.biomedcentral.com/1471-2407/8/19 Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000, 406(6795):536-540. 60. Dissanayake SK, Wade M, Johnson CE, O'Connell MP, Leotlela PD, French AD, Shah KV, Hewitt KJ, Rosenthal DT, Indig FE, Jiang Y, Nick- oloff BJ, Taub DD, Trent JM, Moon RT, Bittner M, Weeraratna AT: The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem 2007, 282(23):17259-17271. 61. Kao YR, Shih JY, Wen WC, Ko YP, Chen BM, Chan YL, Chu YW, Yang PC, Wu CW, Roffler SR: Tumor-associated antigen L6 and the invasion of human lung cancer cells. Clin Cancer Res 2003, 9(7):2807-2816. 62. Gonzalez AM, Gonzales M, Herron GS, Nagavarapu U, Hopkinson SB, Tsuruta D, Jones JC: Complex interactions between the lam- inin alpha 4 subunit and integrins regulate endothelial cell behavior in vitro and angiogenesis in vivo. Proc Natl Acad Sci U S A 2002, 99(25):16075-16080. 63. French J, Stirling R, Walsh M, Kennedy HD: The expression of Ras- GTPase activating protein SH3 domain-binding proteins, G3BPs, in human breast cancers. Histochem J 2002, 34(5):223-231. 64. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M: Obstacles to cancer immunotherapy: expression of membrane comple- ment regulatory proteins (mCRPs) in tumors. Mol Immunol 2003, 40(2-4):109-123. 65. Philip S, Kundu GC: Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcu- min (diferulolylmethane) down-regulates these pathways. J Biol Chem 2003, 278(16):14487-14497. 66. Ruiter DJ, Mattijssen V, Broecker EB, Ferrone S: MHC antigens in human melanomas. Semin Cancer Biol 1991, 2(1):35-45. 67. Weeraratna AT, Becker D, Carr KM, Duray PH, Rosenblatt KP, Yang S, Chen Y, Bittner M, Strausberg RL, Riggins GJ, Wagner U, Kallion- iemi OP, Trent JM, Morin PJ, Meltzer PS: Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene 2004, 23(12):2264-2274. 68. Bernsen MR, Hakansson L, Gustafsson B, Krysander L, Rettrup B, Ruiter D, Hakansson A: On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases. Br J Cancer 2003, 88(3):424-431. 69. Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ, Pajares R, Martinez-Tello FJ, Hortelano CM, Piris MA, Rodriguez-Per- alto JL: Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microar- ray-based study. Am J Pathol 2004, 164(1):193-203. 70. Altomonte M, Fonsatti E, Visintin A, Maio M: Targeted therapy of solid malignancies via HLA class II antigens: a new biothera- peutic approach? Oncogene 2003, 22(42):6564-6569. 71. Mandruzzato S, Callegaro A, Turcatel G, Francescato S, Montesco MC, Chiarion-Sileni V, Mocellin S, Rossi CR, Bicciato S, Wang E, Mar- incola FM, Zanovello P: A gene expression signature associated with survival in metastatic melanoma. J Transl Med 2006, 4:50. 72. Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C, Corbu A, Perra MT, Sirigu P: The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the progno- sis of cutaneous malignant melanoma with vertical growth phase. Cancer 2005, 104(6):1246-1254. 73. van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K, Ferrone S: Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988, 48(4):1019-1025. 74. Rangel LB, Agarwal R, Sherman-Baust CA, Mello-Coelho V, Pizer ES, Ji H, Taub DD, Morin PJ: Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers. Cancer Biol Ther 2004, 3(10):1021-1027. 75. Shy ME, Hobson G, Jain M, Boespflug-Tanguy O, Garbern J, Sperle K, Li W, Gow A, Rodriguez D, Bertini E, Mancias P, Krajewski K, Lewis R, Kamholz J: Schwann cell expression of PLP1 but not DM20 is necessary to prevent neuropathy. Ann Neurol 2003, 53(3):354-365. 76. Skubitz KM, Skubitz AP: Differential gene expression in uterine leiomyoma. J Lab Clin Med 2003, 141(5):297-308. 77. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, Weber BL, Nathanson KL, Phillips DJ, Herlyn M, Schadendorf D, Dummer R: Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pig- ment Cell Res 2006, 19(4):290-302. 78. Stolt CC, Rehberg S, Ader M, Lommes P, Riethmacher D, Schachner M, Bartsch U, Wegner M: Terminal differentiation of myelin- forming oligodendrocytes depends on the transcription fac- tor Sox10. Genes Dev 2002, 16(2):165-170. 79. Potterf SB, Furumura M, Dunn KJ, Arnheiter H, Pavan WJ: Tran- scription factor hierarchy in Waardenburg syndrome: regu- lation of MITF expression by SOX10 and PAX3. Hum Genet 2000, 107(1):1-6. 80. Levy C, Khaled M, Fisher DE: MITF: master regulator of melano- cyte development and melanoma oncogene. Trends Mol Med 2006. 81. Steingrimsson E, Copeland NG, Jenkins NA: Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet 2004, 38:365-411. 82. Loercher AE, Tank EM, Delston RB, Harbour JW: MITF links differ- entiation with cell cycle arrest in melanocytes by transcrip- tional activation of INK4A. J Cell Biol 2005, 168(1):35-40. 83. Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert MD, Denat L, Larue L, Goding CR: Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 2005, 433(7027):764-769. 84. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramas- wamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR: Integrative genomic analyses identify MITF as a lineage sur- vival oncogene amplified in malignant melanoma. Nature 2005, 436(7047):117-122. 85. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, Nishimura EK, Golub TR, Fisher DE: Critical role of CDK2 for melanoma growth linked to its melanocyte-specific tran- scriptional regulation by MITF. Cancer Cell 2004, 6(6):565-576. 86. Busca R, Berra E, Gaggioli C, Khaled M, Bille K, Marchetti B, Thyss R, Fitsialos G, Larribere L, Bertolotto C, Virolle T, Barbry P, Pouyssegur J, Ponzio G, Ballotti R: Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription fac- tor (MITF) in melanoma cells. J Cell Biol 2005, 170(1):49-59. 87. McGill GG, Haq R, Nishimura EK, Fisher DE: c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem 2006, 281(15):10365-10373. 88. Gaggioli C, Robert G, Bertolotto C, Bailet O, Abbe P, Spadafora A, Bahadoran P, Ortonne JP, Baron V, Ballotti R, Tartare-Deckert S: Tumor-Derived Fibronectin Is Involved in Melanoma Cell Invasion and Regulated by V600E B-Raf Signaling Pathway. J Invest Dermatol 2006. 89. White JM: ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol 2003, 15(5):598-606. 90. Sahoo S, Brickley DR, Kocherginsky M, Conzen SD: Coordinate expression of the PI3-kinase downstream effectors serum and glucocorticoid-induced kinase (SGK-1) and Akt-1 in human breast cancer. Eur J Cancer 2005, 41(17):2754-2759. 91. Chen C, Li M, Chai H, Yang H, Fisher WE, Yao Q: Roles of neuropi- lins in neuronal development, angiogenesis, and cancers. World J Surg 2005, 29(3):271-275. 92. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, Wu T, Niinobe M, Yoshikawa K, Hannigan GE, Halaban R: Expression profiling reveals novel pathways in the transformation of melanocytes to melano- mas. Cancer Res 2004, 64(15):5270-5282. 93. de Souza GA, Godoy LM, Teixeira VR, Otake AH, Sabino A, Rosa JC, Dinarte AR, Pinheiro DG, Silva WA Jr., Eberlin MN, Chammas R, Greene LJ: Proteomic and SAGE profiling of murine melanoma progression indicates the reduction of proteins responsible for ROS degradation. Proteomics 2006, 6(5):1460-1470. 94. Bernard K, Litman E, Fitzpatrick JL, Shellman YG, Argast G, Polvinen K, Everett AD, Fukasawa K, Norris DA, Ahn NG, Resing KA: Func- tional proteomic analysis of melanoma progression. Cancer Res 2003, 63(20):6716-6725. Page 17 of 18 (page number not for citation purposes)